Literature DB >> 14752252

Effects of simvastatin on plasma lipoproteins and response to arterial injury in wild-type and apolipoprotein-E-deficient mice.

Robin P Choudhury1, Angela L Carrelli, Joshua D Stern, Igor Chereshnev, Raymond Soccio, Valerie I Elmalem, John T Fallon, Edward A Fisher, Ernane D Reis.   

Abstract

OBJECTIVE: To test the non-lipid-lowering effects of simvastatin on the response to injury in normolipidemic and hyperlipidemic mice. METHODS AND
RESULTS: Wild-type (WT) mice (n = 40) and hyperlipidemic apolipoprotein-E-deficient (apoE(-/-)) mice (n = 40) received normal chow or chow containing simvastatin 100 mg/kg/day prior to bilateral femoral artery wire injury. Intimal hyperplasia and plasma cholesterol concentration were quantified after 4 weeks. Plasma cholesterol in WT mice treated or untreated with simvastatin was similar (100.9 +/- 6.6 vs. 94.3 +/- 17.5 mg/dl). Simvastatin did not affect intimal hyperplasia. In apoE(-/-) mice, intimal hyperplasia was increased 2.3-fold relative to WT mice (17090 +/- 4998 vs. 39490 +/- 16190; p < 0.001). In apoE(-/- )mice, simvastatin caused a paradoxical increase in plasma cholesterol (1094 +/- 60.3 vs. 658 +/- 66.8 mg/dl; p < 0.001), confirmed by FPLC. This was associated with a further increase in intimal area (39490 +/- 16190 vs. 55420 +/- 22590 mm(2); p < 0.01).
CONCLUSIONS: (1). Simvastatin had no effect on plasma cholesterol or the response to arterial injury in normolipidemic WT mice; (2). hyperlipidemia was associated with markedly increased intimal hyperplasia, and (3). simvastatin treatment of apoE(-/-) mice caused paradoxical hyperlipidemia and increased intimal hyperplasia. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14752252     DOI: 10.1159/000076436

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  5 in total

1.  Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts.

Authors:  Liyan Zhuang; Jayoung Kim; Rosalyn M Adam; Keith R Solomon; Michael R Freeman
Journal:  J Clin Invest       Date:  2005-03-17       Impact factor: 14.808

2.  Bone marrow endothelial progenitors in atherosclerotic plaque resolution.

Authors:  Longbiao Yao; Janet Heuser-Baker; Oana Herlea-Pana; Jana Barlic-Dicen
Journal:  Organogenesis       Date:  2013-01-01       Impact factor: 2.500

3.  Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.

Authors:  Guohua Song; Jia Liu; Zhenmei Zhao; Yang Yu; Hua Tian; Shutong Yao; Guoli Li; Shucun Qin
Journal:  Lipids Health Dis       Date:  2011-01-18       Impact factor: 3.876

4.  Skeletal muscle metabolic adaptations to endurance exercise training are attainable in mice with simvastatin treatment.

Authors:  William M Southern; Anna S Nichenko; Daniel D Shill; Corey C Spencer; Nathan T Jenkins; Kevin K McCully; Jarrod A Call
Journal:  PLoS One       Date:  2017-02-16       Impact factor: 3.240

5.  Circulating Markers Reflect Both Anti- and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice.

Authors:  Birong Liao; Eileen McCall; Karen Cox; Chung-Wein Lee; Shuguang Huang; Richard E Higgs; Li-Chun Chio; Eugene Zhen; John E Hale; Nancy K Jackson; Pamela G Rutherford; Xiao-di Huang; Donetta Gifford-Moore; Kwan Hui; Kevin Duffin; Kenneth E Gould; Mark Rekhter
Journal:  Biomark Insights       Date:  2008-03-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.